Detalles de la búsqueda
1.
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Haematologica
; 105(1): e22-e25, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048356
2.
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.
Front Oncol
; 13: 1200914, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37719008
3.
Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma.
Hematol Oncol Stem Cell Ther
; 16(2): 133-143, 2023 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34562407
4.
Physicians' Perspectives on HL7 Information Policy Sensitive Value Set: A Validation Study through Health Concept Categorization.
Healthcare (Basel)
; 11(21)2023 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37957990
5.
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.
Adv Hematol
; 2022: 4450824, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35103064
Resultados
1 -
5
de 5
1
Próxima >
>>